Sejung Park

473 total citations
22 papers, 274 citations indexed

About

Sejung Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sejung Park has authored 22 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Sejung Park's work include Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Sejung Park is often cited by papers focused on Gastric Cancer Management and Outcomes (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Sejung Park collaborates with scholars based in South Korea. Sejung Park's co-authors include Sun Young Rha, Hyun Cheol Chung, Choong‐kun Lee, Chung Mo Nam, Minkyu Jung, Hyung Soon Park, Beodeul Kang, Hyo Song Kim, Min Hwan Kim and Hye Jin Choi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Sejung Park

19 papers receiving 272 citations

Peers

Sejung Park
Takeshi Kawakami Japan
Ken Kato Japan
Markus Moehler Germany
J-P. Metges France
И. А. Покатаев Russia
Manuela Machado Portugal
Heejung Chae South Korea
Svetlana Tafjord Norway
Nanfeng Fan China
Seung Tae Kim South Korea
Takeshi Kawakami Japan
Sejung Park
Citations per year, relative to Sejung Park Sejung Park (= 1×) peers Takeshi Kawakami

Countries citing papers authored by Sejung Park

Since Specialization
Citations

This map shows the geographic impact of Sejung Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sejung Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sejung Park more than expected).

Fields of papers citing papers by Sejung Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sejung Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sejung Park. The network helps show where Sejung Park may publish in the future.

Co-authorship network of co-authors of Sejung Park

This figure shows the co-authorship network connecting the top 25 collaborators of Sejung Park. A scholar is included among the top collaborators of Sejung Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sejung Park. Sejung Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lee, Shirley, Soo Jin Park, Kichul Shin, et al.. (2025). OP01-5 Efficacy and safety of larotrectinib in NTRK fusion-positive solid tumor patients: A multi-center retrospective study. ESMO Open. 10. 104008–104008.
3.
Kim, Yong Joon, Myeongjee Lee, Eun Hwa Kim, et al.. (2024). Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study. Cancer Letters. 596. 216998–216998. 6 indexed citations
4.
Lee, Choong‐kun, Soon Sung Kwon, Woo Sun Kwon, et al.. (2023). Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer. Clinical Chemistry and Laboratory Medicine (CCLM). 62(1). 178–186. 5 indexed citations
5.
6.
Kim, Chang Gon, Minkyu Jung, Hyo Song Kim, et al.. (2023). Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer. Journal of Clinical Oncology. 41(27). 4394–4405. 27 indexed citations
7.
Lee, Choong‐kun, Sun Young Rha, Hyo Song Kim, et al.. (2022). A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nature Communications. 13(1). 6002–6002. 33 indexed citations
8.
Lee, Choong‐kun, Hong Jae Chon, Jaekyung Cheon, et al.. (2022). Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). ˜The œLancet. Gastroenterology & hepatology. 8(1). 56–65. 75 indexed citations
9.
Rha, Sun Young, Choong‐kun Lee, Hyo Song Kim, et al.. (2022). The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC).. Journal of Clinical Oncology. 40(16_suppl). 4001–4001. 3 indexed citations
10.
Bae, Hyun-Joo, Woo Sun Kwon, Tae Soo Kim, et al.. (2021). Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. Cellular Oncology. 44(6). 1387–1403. 5 indexed citations
11.
Park, Ji Soo, Eun‐Ah Choe, Sejung Park, et al.. (2021). Detection of asymptomatic recurrence improves survival of gastric cancer patients. Cancer Medicine. 10(10). 3249–3260. 15 indexed citations
12.
Lee, Seo-Young, Seul‐Gi Kim, Sejung Park, et al.. (2021). Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. Journal of Clinical Oncology. 39(15_suppl). e16578–e16578. 1 indexed citations
13.
14.
15.
Park, Hyung Soon, Woo Sun Kwon, Sejung Park, et al.. (2019). Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. Journal for ImmunoTherapy of Cancer. 7(1). 268–268. 28 indexed citations
16.
Lee, Jii Bum, Hyung Soon Park, Sejung Park, et al.. (2019). Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. Cancer Research and Treatment. 51(4). 1578–1588. 9 indexed citations
17.
Shin, Su‐Jin, Sejung Park, Min Hwan Kim, et al.. (2019). Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. The Oncologist. 24(11). e1108–e1114. 19 indexed citations
18.
Park, Sinyoung, Chung Mo Nam, Sejung Park, et al.. (2018). ‘Screening audit’ as a quality assurance tool in good clinical practice compliant research environments. BMC Medical Ethics. 19(1). 30–30. 2 indexed citations
19.
Kang, Huapyong, Jung Hyun Jo, Moon Jae Chung, et al.. (2018). FOLFIRINOX versus gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer: a single-center cohort study. Annals of Oncology. 29. v45–v45. 5 indexed citations
20.
Yi, Seong Yoon, Hong-Sik Kim, In Gyu Hwang, et al.. (2007). Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Journal of Clinical Oncology. 25(18_suppl). 15111–15111.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takeshi Kawakami Breakdown of academic impact, for papers by Ken Kato Breakdown of academic impact, for papers by Markus Moehler Breakdown of academic impact, for papers by J-P. Metges Breakdown of academic impact, for papers by И. А. Покатаев Breakdown of academic impact, for papers by Manuela Machado Breakdown of academic impact, for papers by Heejung Chae Breakdown of academic impact, for papers by Svetlana Tafjord Breakdown of academic impact, for papers by Nanfeng Fan Breakdown of academic impact, for papers by Seung Tae Kim
Rankless by CCL
2026